BioInvent Q1 2025: Focus on BI-1808 in T-cell Lymphoma - Redeye

Redeye comments on BioInvent’s first quarter in 2025. After our last update, BI-1808 obtained both Fast Track and Orphan Drug designations from the FDA. It is on track for a phase IIa readout by mid-year. Other programmes, including BI-1206, are also set for important readouts this year. Furthermore, the partnered asset mezagitamab moved into phase III, triggering a milestone payment.

Länk till analysen i sin helhet: https://www.redeye.se/research/1101131/bioinvent-q1-2025-focus-on-bi-1808-in-t-cell-lymphoma?utm_source=finwire&utm_medium=RSS